Atlas FDA

ADVIA CENTAUR ANTI-HBS2 MASTER CURVE MATERIALS

FDA premarket approval P100039/S002 · decided 2013-09-26

Approval details

PMA number
P100039
Supplement
S002
Supplement type
Real-Time Process
Supplement reason
Change Design/Components/Specifications/Material
Trade name
ADVIA CENTAUR ANTI-HBS2 MASTER CURVE MATERIALS
Generic name
Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen)
Applicant
Siemens Healthcare Diagnostics, Inc.
Date received
2012-09-28
Decision date
2013-09-26
Days to decision
363 days
Decision code
APPR
Product code
LOM
Advisory committee
Microbiology
Expedited review
No
Location
Tarrytown, NY
Statement
APPROVAL FOR THE AD VIA CENTAUR ANTI-HBS2 (AHBS2) MASTER CURVEMATERIAL. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME AD VIA CENTAUR ANTIHBS2(AHBS2) ASSAY, ADVIA CENTAUR ANTI-HBS2 (AHBS2) QUALITY CONTROL MATERIAL, ANDADVIA CENTAUR ANTI-HBS2 (AHBS2) MASTER CURVE MATERIAL AND IS INDICATED FOR:ADVIA CENTAUR ANTI-HBS2 (AHBS2) ASSAY: THE ADVIA CENTAUR ANTI-HBS2 ASSAY IS AN IN VITRO DIAGNOSTIC IMMUNOASSAY FOR THE QUALITATIVEAND QUANTITATIVE DETENNINATION OF TOTAL ANTIBODIES TO HEPATIT

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Atellica CH Acetaminophen 2 (ACTM) (K261364)Siemens Healthcare Diagnostics, Inc.2026-07-24
Atellica CH Diazo Total Bilirubin (D_TBil) (K251998)Siemens Healthcare Diagnostics, Inc.2026-02-27
Atellica® IM TSH3-Ultra II (TSH3ULII) (K251543)Siemens Healthcare Diagnostics, Inc.2026-02-06
Atellica IM Total PSA II (tPSAII) (K251630)Siemens Healthcare Diagnostics, Inc.2026-01-05
ADVIA Centaur Anti-Thyroglobulin II (aTgII) (K250816)Siemens Healthcare Diagnostics, Inc.2025-12-04
ADVIA Centaur Anti-Thyroid Peroxidase II (K250250)Siemens Healthcare Diagnostics, Inc.2025-10-17
Atellica IM Thyroglobulin (Tg) (K242981)Siemens Healthcare Diagnostics, Inc.2025-06-20
Atellica® CH Creatinine_3 (Crea3) (K242685)Siemens Healthcare Diagnostics, Inc.2024-12-04